Literature DB >> 15316714

Differential effects of reboxetine and citalopram on hand-motor function in patients suffering from major depression.

Ulrich Hegerl1, Roland Mergl, Verena Henkel, Oliver Pogarell, Florian Müller-Siecheneder, Thomas Frodl, Georg Juckel.   

Abstract

RATIONALE: Motor dysfunctions might be a more common side effect of serotonergic than noradrenergic antidepressants. However, the effects of antidepressants on motor function in depression have rarely been analyzed systematically. Computerized methods allow the objective registration of drug-induced motor dysfunction and were applied in this study.
OBJECTIVES: To examine the effects of a selective noradrenaline re-uptake inhibitor (NARI) (reboxetine) and a selective serotonin re-uptake inhibitor (SSRI) (citalopram) on hand-motor function in patients with major depression.
METHODS: Different types of hand movements (drawing of circles and handwriting probes) were recorded and analyzed in 16 acutely depressed inpatients receiving citalopram (30-60 mg/day) and 12 acutely depressed inpatients treated with reboxetine (4-8 mg/day), using a digitizing tablet for the analysis of movement dynamics. Both groups were comparable regarding mean age (42-43 years), gender, handedness (preponderance of right-handers) and the mean baseline HAMD score (about 27). Five kinematical parameters reflecting velocity, regularity and degree of automation of hand movements have been computed.
RESULTS: Reboxetine had significantly more favorable effects on fine motor function (increased velocity of rapid hand movements) in depressed patients than citalopram. These differences became obvious when patients conducted more complex tasks and are not explained by differential antidepressant effects.
CONCLUSIONS: Our findings are in line with the hypothesis that SSRI tend to have small, but more pronounced negative effects on motor function than NARI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316714     DOI: 10.1007/s00213-004-1983-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  Digitized analysis of handwriting and drawing movements in healthy subjects: methods, results and perspectives.

Authors:  R Mergl; P Tigges; A Schröter; H J Möller; U Hegerl
Journal:  J Neurosci Methods       Date:  1999-08-15       Impact factor: 2.390

2.  Control of simultaneous movements distinguishes depressive motor retardation from Parkinson's disease and neuroleptic parkinsonism.

Authors:  S Fleminger
Journal:  Brain       Date:  1992-10       Impact factor: 13.501

3.  Effect of reboxetine on depression in Parkinson's disease patients.

Authors:  Matthias R Lemke
Journal:  J Clin Psychiatry       Date:  2002-04       Impact factor: 4.384

4.  The effects of reboxetine on autonomic and cognitive functions in healthy volunteers.

Authors:  M Siepmann; M Mück-Weymann; P Joraschky; W Kirch
Journal:  Psychopharmacology (Berl)       Date:  2001-09       Impact factor: 4.530

5.  Assessment of handedness using a digitizing tablet: a new method.

Authors:  V Henkel; R Mergl; G Juckel; D Rujescu; P Mavrogiorgou; I Giegling; H Möller; U Hegerl
Journal:  Neuropsychologia       Date:  2001       Impact factor: 3.139

6.  The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance.

Authors:  J S Kerr; J Powell; I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1996-08       Impact factor: 4.335

7.  Depressive retardation and treatment with fluoxetine: assessment of the motor component.

Authors:  B Sabbe; J van Hoof; W Hulstijn; F Zitman
Journal:  J Affect Disord       Date:  1997-03       Impact factor: 4.839

8.  A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group.

Authors:  I H Richard; R Kurlan
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

9.  Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.

Authors:  J M Ferguson; J Mendels; G E Schwart
Journal:  Int Clin Psychopharmacol       Date:  2002-03       Impact factor: 1.659

Review 10.  The safety and tolerability of citalopram.

Authors:  C Muldoon
Journal:  Int Clin Psychopharmacol       Date:  1996-03       Impact factor: 1.659

View more
  3 in total

1.  No effects of enhanced central norepinephrine on finger-sequence learning and attention.

Authors:  Christian Plewnia; Julia Hoppe; Christian Gerloff
Journal:  Psychopharmacology (Berl)       Date:  2006-06-10       Impact factor: 4.530

2.  Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients.

Authors:  Maurits E L Arbouw; Kris L L Movig; Cees Neef; Henk-Jan Guchelaar; Toine C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

Review 3.  Citalopram versus other anti-depressive agents for depression.

Authors:  Andrea Cipriani; Marianna Purgato; Toshi A Furukawa; Carlotta Trespidi; Giuseppe Imperadore; Alessandra Signoretti; Rachel Churchill; Norio Watanabe; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.